News
MRVI
7.68
-0.26%
-0.02
Video: Nvidia slump deepens, drags down futures
TipRanks · 19h ago
Maravai LifeSciences Price Target Announced at $11.00/Share by Keybanc
Dow Jones · 21h ago
Maravai LifeSciences Raised to Overweight From Sector Weight by Keybanc
Dow Jones · 21h ago
Keybanc Upgrades Maravai LifeSciences to Overweight, Announces $11 Price Target
Benzinga · 22h ago
KeyBanc upgrades Maravai to Overweight on midterm election results
TipRanks · 23h ago
Maravai Lifesciences upgraded to Overweight from Sector Weight at KeyBanc
TipRanks · 1d ago
Weekly Report: what happened at MRVI last week (1102-1106)?
Weekly Report · 4d ago
Maravai LifeSciences Holdings Consensus Price Target Raised 11.76% to $9.69
NASDAQ · 4d ago
Maravai LifeSciences Holdings (MRVI) Lifted Guidance, Is The Stock Still Cheap?
Simply Wall St · 6d ago
Improved Earnings Could Reset The Case For Maravai LifeSciences Stock (MRVI)
Simply Wall St · 11/06 05:22
Maravai LifeSciences (MRVI) Q3 2026 Earnings Call Transcript
NASDAQ · 11/05 20:28
Maravai Lifesciences price target raised to $10 from $7 at Craig-Hallum
TipRanks · 11/05 14:37
Missed Maravai LifeSciences' 169% Gain? Here Is What Holders Saw
Simply Wall St · 11/05 03:42
Maravai LifeSciences Holdings, Inc. Reports Third Quarter 2026 Financial Results
NASDAQ · 11/05 01:29
Maravai LifeSciences Q3 2026 Earnings Call Transcript
Benzinga · 11/04 22:49
Maravai Lifesciences raises FY26 revenue view to $212M-$216M from $205M-$215M
TipRanks · 11/04 21:23
Maravai LifeSciences Raises FY2026 Sales Guidance from $205.000M-$215.000M to $212.000M-$216.000M vs $211.767M Est
Benzinga · 11/04 21:20
Maravai Lifesciences reports Q3 EPS (9c), consensus (6c)
TipRanks · 11/04 21:15
Maravai LifeSciences Holdings Non-GAAP EPS of -$0.03 beats by $0.03, revenue of $45.9M beats by $2.34M
Seeking Alpha · 11/04 21:08
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 11/04 21:05
More
Webull provides a variety of real-time MRVI stock news. You can receive the latest news about Maravai Lifesciences Holdings, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About MRVI
Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products and services to enable the development of drugs, therapeutics, vaccines, and diagnostics, and support research on human disease. Its segments include TriLink and Cygnus. Its TriLink segment provides nucleic acid products and related services, including messenger ribonucleic acid (mRNA), oligonucleotides, CleanCap mRNA capping technology, ModTail poly(A) tail modification technology, synthesis inputs, nucleoside triphosphates, enzymes, and mRNA manufacturing services. Its Cygnus segment provides biologics safety testing products and services, including host cell protein enzyme-linked immunosorbent assay (ELISA) kits, impurity detection assays, viral clearance prediction tools, ancillary reagents, and custom analytical services. Its TriLink and Cygnus segments produce materials used in research and biopharmaceutical production, clinical trial vaccines and vaccine support products.